Aspirin for primary prevention of cardiovascular disease: What do the current USPSTF guidelines say?
Journal
Cleveland Clinic journal of medicine
ISSN: 1939-2869
Titre abrégé: Cleve Clin J Med
Pays: United States
ID NLM: 8703441
Informations de publication
Date de publication:
01 05 2023
01 05 2023
Historique:
medline:
3
5
2023
pubmed:
2
5
2023
entrez:
1
5
2023
Statut:
epublish
Résumé
The 2022 US Preventive Services Task Force (USPSTF) recommendation notes that the decision to initiate daily aspirin therapy for primary prevention of cardiovascular disease (CVD) should be made on a case-by-case basis for adults ages 40 to 59 with a 10% or greater 10-year CVD risk. The recommendation applies to those without signs or symptoms of clinically evident CVD who are not at an increased risk of bleeding. Clinicians are encouraged to use their judgment in weighing the risks and benefits of aspirin therapy, while taking patient preference into account for patients ages 40 to 60.
Identifiants
pubmed: 37127334
pii: 90/5/287
doi: 10.3949/ccjm.90a.22087
doi:
Substances chimiques
Aspirin
R16CO5Y76E
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
287-291Informations de copyright
Copyright © 2023 The Cleveland Clinic Foundation. All Rights Reserved.